Breast Cancer

Patients with breast cancer who still had residual disease after undergoing neoadjuvant chemotherapy and surgery had improved survival outcomes with the addition of adjuvant capecitabine to standard treatment.

Premenopausal women with luminal A breast tumors received no benefit from treatment with adjuvant chemotherapy.

Breast cancer survivors with therapy-related leukemia were found to have personal and family histories that suggested an inherited risk for cancer.

Ahead of SABCS we discuss the biology and treatment of ductal carcinoma in situ, as well as research into prognostic indicators that could help guide treatment decisions.

Survival of women initially diagnosed with stage IV breast cancer has improved in the last 20 years, according to results of a retrospective cohort study.

Cancer survivors treated with anthracycline-based chemotherapies exhibited poorer performance of certain cognitive skills.

Women who previously had a false-positive mammogram or biopsy are at higher risk for developing breast cancer for at least 10 years, according to a new study.

In this interview we discuss the new American Cancer Society breast cancer screening guidelines and find out how they stack up with other recommendations for mammography screening.

Serum matrix metalloproteinase 9 (MMP-9) and HER2 extra-cellular domain (HER2-ECD) might be predictive biomarkers for the metastasis of breast cancer to the brain, according to a case-control study.

Dual HER2 blockade with trastuzumab and lapatinib was no better than trastuzumab alone in producing pathologic complete responses in metastatic HER2-positive breast cancer patients in the neoadjuvant setting, according to a new study.

Researchers have developed a blood-based assay that detects ESR1 mutations in circulating tumor DNA and could predict treatment failure in breast cancer patients.

A 31-year-old woman presents with a nodule in the breast. After further evaluation, a biopsy is performed. What is your diagnosis?

The use of afatinib failed to show a benefit in HER2-positive breast cancer patients with progressive brain metastases.

A 43-year-old woman presents with a lesion in the right nipple. After further evaluation, a biopsy is performed. What is your diagnosis?

This commentary addresses our perspectives from a regulatory standpoint, as well as some controversies related to the use of neoadjuvant therapy as a platform for drug development.

Identifying breast cancer patients who are at low risk for chemotherapy-induced nausea and vomiting before the start of treatment may help avoid unnecessary use of antiemetic medications without compromising quality of care.

We acknowledge that the “more is better” approach may not always hold true. For example, preclinical data provided a rationale for combining pertuzumab with T-DM1, but recent reports suggest that this strategy may not prove more effective than single-agent T-DM1 therapy in the clinic.

The preferred status of CLEOPATRA-like regimens in the first-line HER2-positive metastatic breast cancer setting has recently been challenged by antibody-drug conjugate regimens based on ado-trastuzumab emtansine (T-DM1).

In this review, we will discuss multidisciplinary considerations in treating patients with neoadjuvant therapy and highlight areas of controversy and ongoing research.

The biologic rationale for the initial evaluation of preoperative chemotherapy or neoadjuvant chemotherapy in patients with early-stage breast cancer was based on experimental and clinical observations regarding primary tumor cell growth and dissemination.

Preoperative bevacizumab may predominantly benefit breast cancer patients with a high baseline microvessel density, according to a new study.

The overall risk of developing a second primary thyroid or breast tumor is higher in patients with prior breast or thyroid cancer.

New breast cancer screening guidelines from the American Cancer Society recommend pushing the start of screening back by 5 years and screening every other year rather than annually starting at age 55.

An analysis of different breast cancer screening schedules suggests that biennial mammograms may be acceptable for postmenopausal women, but that premenopausal women likely need more frequent screening.

A 35-year-old woman presents with a mass in the left breast. After further evaluation, a biopsy is performed. What is your diagnosis?